Skip to main content

Matador Resources Co

For the period ended Sep 30, 2024. Filed Oct 25, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Oct 25, 2024

MTDR$50.41+1.1%Stored close · as of Nov 6, 2026

What changed in Risk Factors?

Read the current filing

Previous report: 10-Q

Period ended 2024-06-30; filed 2024-07-26.

0001520006-24-000165

Item 1A. Risk Factors

Current report: 10-Q

Period ended 2024-09-30; filed 2024-10-25.

0001520006-24-000209

Item 1A. Risk Factors

The baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.

Compared 9 previous paragraphs and 2 current paragraphs.

1 unchanged; 1 reworded; 0 added; 7 removed; 0 previous and 0 current paragraphs rearranged.

Tables are not compared: 0 previous and 0 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.

A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.

Removed paragraphs (7)

Previous report

The consummation of the Ameredev Acquisition is subject to a number of conditions that may not be satisfied or completed on a timely basis or at all. Accordingly, there can be no assurance as to when or if the Ameredev Acquisition will be completed, and the failure to complete the Ameredev Acquisition could have a material and adverse effect on our business, financial condition, results of operations and cash flows.

Previous report

Although we expect to complete the Ameredev Acquisition late in the third quarter of 2024, there can be no assurances as to the exact timing of the closing or that the Ameredev Acquisition will be completed at all. The consummation of the Ameredev Acquisition is subject to the satisfaction or waiver of a number of conditions contained in the related securities purchase agreement, including, among others, the expiration or termination of any applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. Such conditions, some of which are beyond our control, may not be satisfied or waived in a timely manner or at all and therefore make the completion and timing of the Ameredev Acquisition uncertain. In addition, the securities purchase agreement contains certain termination rights for both parties, which if exercised will also result in the Ameredev Acquisition not being consummated. Any such termination or any failure to otherwise complete the Ameredev Acquisition could result in various consequences, including, among others: our business being adversely impacted by the failure to pursue other beneficial opportunities due to the time and resources committed by our management to the Ameredev Acquisition, without realizing any of the benefits of completing the Ameredev Acquisition; being required to pay our legal, accounting and other expenses relating to the Ameredev Acquisition; the market price of our common stock being adversely impacted to the extent that the current market price reflects a market assumption that the Ameredev Acquisition will be completed; and negative reactions from the financial markets and customers that may occur if the anticipated benefits of the Ameredev Acquisition are not realized. Such consequences could materially and adversely affect our business, financial condition, results of operations and cash flows.

Previous report

Even if the Ameredev Acquisition is completed, we may be unable to successfully integrate Ameredev’s business into our business or achieve the anticipated benefits of the Ameredev Acquisition.

Previous report

The success of the Ameredev Acquisition will depend, in part, on our ability to realize the anticipated benefits and cost savings from integrating the assets and operations of Ameredev into our business, and there can be no assurance that we will be able to successfully integrate or otherwise realize the anticipated benefits of the Ameredev Acquisition. Difficulties in integrating Ameredev into our company and our ability to manage the combined company may result in us performing differently than expected, in operational challenges or in the delay or failure to realize anticipated expense-related efficiencies and could have a material adverse effect on our business, financial condition, results of operations and cash flows. Potential difficulties that may be encountered in the integration process include, among others:

Previous report

•the inability to successfully integrate Ameredev operationally, in a manner that permits us to achieve the full revenue, expected cash flows and cost savings anticipated from the Ameredev Acquisition;

Previous report

•not realizing anticipated operating synergies; and

Previous report

•potential unknown liabilities and unforeseen expenses, delays or regulatory conditions associated with the Ameredev Acquisition.
Reworded paragraphs (1)

Previous wording

We are subject to various risks and uncertainties in the course of our business. For a discussion of such risks and uncertainties, please see “Item 1A. Risk Factors” in the Annual Report. Except as set forth below, there have been no material changes to the risk factors we have disclosed in the Annual Report.

Current wording

We are subject to various risks and uncertainties in the course of our business. For a discussion of such risks and uncertainties, please see “Item 1A. Risk Factors” in the Annual Report.